Preoperative serum h-FABP concentration is associated with postoperative incidence of acute kidney injury in patients undergoing cardiac surgery by Mehmet Oezkur et al.
Oezkur et al. BMC Cardiovascular Disorders 2014, 14:117
http://www.biomedcentral.com/1471-2261/14/117RESEARCH ARTICLE Open AccessPreoperative serum h-FABP concentration is
associated with postoperative incidence of acute
kidney injury in patients undergoing cardiac
surgery
Mehmet Oezkur1*, Armin Gorski1, Jennifer Peltz1, Martin Wagner2, Maria Lazariotou1, Christoph Schimmer1,
Peter U Heuschmann2,3 and Rainer G Leyh1Abstract
Background: Fatty acid binding protein (FABP) is an intracellular transport protein associated with myocardial
damage size in patients undergoing cardiac surgery. Furthermore, elevated FABP serum concentrations are related
to a number of common comorbidities, such as heart failure, chronic kidney disease, diabetes mellitus, and
metabolic syndrome, which represent important risk factors for postoperative acute kidney injury (AKI). Data are
lacking on the association between preoperative FABP serum level and postoperative incidence of AKI.
Methods: This prospective cohort study investigated the association between preoperative h-FABP serum
concentrations and postoperative incidence of AKI, hospitalization time and length of ICU treatment. Blood samples
were collected according to a predefined schedule. The AKI Network definition of AKI was used as primary
endpoint. All associations were analysed using descriptive and univariate analyses.
Results: Between 05/2009 and 09/2009, 70 patients undergoing cardiac surgery were investigated. AKI was
observed in 45 patients (64%). Preoperative median (IQR) h-FABP differed between the AKI group (2.9 [1.7–4.1] ng/ml)
and patients without AKI (1.7 [1.1–3.3] ng/ml; p = 0.04), respectively. Patients with AKI were significantly older. No
statistically significant differences were found for gender, type of surgery, operation duration, CPB-, or X-Clamp
time, preoperative cardiac enzymes, HbA1c, or CRP between the two groups. Preoperative h-FABP was also correlated
with the length of ICU stay (rs = 0.32, p = 0.007).
Conclusions: We found a correlation between preoperative serum h-FABP and the postoperative incidence of AKI. Our
results suggest a potential role for h-FABP as a biomarker for AKI in cardiac surgery.Background
Fatty Acid Binding Protein (FABP) is an intracellular trans-
port protein responsible for transporting long chained fatty
acids to their destination and has organ specific subtypes
(e.g. heart-type, liver-type and brain-type FABP) [1,2].
Heart-type FABP (h-FABP) is a marker for myocardial is-
chemia and is associated with ECG changes, arrhythmia
and mortality after cardiac surgery [3-8]. Furthermore,
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unless otherwise stated.diabetes mellitus, chronic kidney disease, metabolic syn-
drome and is positively correlated with age [1,4,9-11].
These entities also represent important risk factors for
postoperative acute kidney injury (AKI), which is a com-
mon postoperative complication with an incidence of 20
to 40% after cardiac surgery with high impact on post-
operative mortality [12-20].
Utilizing h-FABP as a single marker for the described var-
iety of risk factors of AKI seems to be possible. But studies
regarding the association of h-FABP’s pre-operative serum
concentration and post-operative outcomes for patients
undergoing operations with cardiopulmonary bypass (CPB)
are lacking. Although postoperative l-FABP has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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has not been investigated as an AKI marker in a cohort
of cardiac surgical patients [14,15,17,21-24].
In the current study, we aimed to explore the association
between preoperative h-FABP levels and the occurrence
of AKI in patients undergoing cardiac surgery within the
setting of a prospective mono-center cohort study.
Methods
The study protocol was approved by the Ethics Committee
at the University Hospital of Würzburg. Adult (>18 years)
patients scheduled for elective CABG surgery or single valve
repair/replacement in the Department of Cardio-Thoracic
Surgery at the University Hospital Würzburg, Germany
were eligible if they provided written informed consent.
Exclusion criteria comprised chronic kidney disease stage
3 or greater (i.e. eGFRCKD-EPI <30 ml/min/1.73 m
2), off
pump surgery, acute inflammation (defined by C-reactive
protein (CRP) > 4 mg/dl, and procalcitonin (PCT) > 1.0 μg/l),
history of immunological or musculoskeletal disorders,
stroke within 30 day prior to admission, preoperative
resuscitation, preoperative electrical cardioversion, sal-
vage or urgent operations (defined as preoperative be-
ginning of cardiopulmonary support). All patients were
operated with blood cardioplegia at 4°C applied every
20 minutes and in mild hypothermic perfusion (32°C).
Primary endpoint was defined as incidence of AKI ac-
cording to acute kidney injury network (AKIN) (increase
of serum creatinine by ≥0.3 within 48 hours), while base-
line was set at admission to hospital, which was usually
the day before operation; secondary endpoints were
mechanical ventilation time, length of ICU stay, and
hospitalization time [16].
Standard demographic data of patients was collected
prospectively including sex, age, weight, height and waist
circumference at the time of operation. Intraoperative
data such as operation time, paracorporal bypass time
and aortic cross clamping time were noted. Blood sam-
ples were taken at hospital admission, after induction of
anaesthesia 30 minutes, 6, 24 and 48 hours after aortic
cross clamping. Length of mechanical ventilation, length
of ICU stay and hospitalization time was listed.
h-FABP was measured by ELISA (HK402 HUMAN H-
FABP ELISE KIT, Hycult biotech, Netherlands) in ng/ml
in our own laboratory from blood samples taken after
introduction of anaesthesia and 30 minutes after aortic
clamping. Creatinine was measured in central laboratory
unit of the University of Wurzburg.
Statistical analysis
Continuous variables are presented as mean and standard
deviations or as medians and interquartile ranges. Cat-
egorical variables are presented in percentages. Normal
distribution testing was performed with a Kolmogorov-Smirnov-Test. To test for differences across all groups,
χ2-test, Fisher’s exact test, t-test, Mann–Whitney-U-
Test were used. Correlation analyses were performed
employing Spearman correlation. In logistic regression
analysis modelling we investigated h-FABP, age and
eGFR regarding their association with the risk for AKI.
To assure normal distribution of h-FABP natural log
was used. Two-sided p-values of ≤0.05 were considered
as statistically significant. Analyses were performed
with SPSS Version 21.
Results
A total of 238 consecutive patients admitted to the de-
partment of cardiovascular surgery of the University of
Würzburg between 05/2009 and 09/2009 were screened
for participation in the study. Of those, 122 patients met
the inclusion criteria and 70 were included in the study.
Reasons for exclusion were: urgent surgery (32 patients),
chronic kidney disease stage 3 or greater (14 patients), off
pump surgery (5 patients), acute inflammation (1 patient).
Patient characteristics at baseline are shown in Table 1.
Patients were predominantly male (80%) with a mean
age of 67(±10) yrs. The mean preoperative eGFR was 88
(±11) ml/min/1.73 m2, 69% (n = 48) of the cohort re-
ceived CABG surgery, while 22 (31%) underwent single
valve replacement. Preoperative median troponin T was
0.01 [IQR: 0.01–0.01].
A total of 45 patients (64.3%) achieved the primary
endpoint of AKI, while only three patients experienced
more severe stages of AKI, including the need for dialy-
sis (4.3%).
Postoperative ischemia markers did not differ signifi-
cantly between the two groups of AKI vs. non-AKI (see
Table 2). Patients with AKI had to remain longer on the
ICU, however, mechanical ventilation time and overall
hospital stay did not differ (Table 3). Preoperative median
(IQR) h-FABP differed between the AKI group (2.9 [1.7–
4.1] ng/m) and patients without AKI (1.7 [1.1–3.3] ng/ml;
p = 0.04), respectively. Preoperative h-FABP was also cor-
related with the length of ICU stay (rs = 0.32, p = 0.007)
and with hospitalization time (rs = 0.308; p = 0.009). No
relation was found for age with the length of ICU stay
(rs = 0.089, p = 0.47). h-FABP was associated with preopera-
tive creatinine (rs = 0.404, p = 0.001), eGFR (rs = −0.603,
p < 0.001), and myoglobin levels (rs = 0.610, p < 0.001).
Although a number of preoperative variables (e.g., age,
waist circumference, HbA1c, operation duration, x-clamp
time, all p < 0.05) differed between CABG and valve pa-
tients, there was no statistically significant difference in
the incidence of the primary endpoint AKI (p = 0.29). In
logistic regression analysis, the association of elevated h-
FABP levels with an increased risk for AKI diminished
after adjustment for age and preoperative kidney function
(Table 4). However, in the final elimination model only
Table 1 Preoperative characteristics
Variable All patients (n = 70) AKI (n = 45) No AKI (n = 25) P-value
h-FABP [ng/dl] 2.9 (1.4–3.9) 2.9 (1.7–4.1) 1.7 (1.1–3.3) 0.039
Age (yr) 67 (±10) 69 (±9) 64 (±11) 0.016
Male 56 (80%) 37 (82%) 19 (76%) 0.76
CABG 48 (69%) 33 (73%) 15 (60%) 0.29
Preoperative creatinine [mg/dl] 1.0 (±0.3) 1.0 (±0.2) 0.9 (±0.1) 0.50
eGFR–CKDEPI preoperative [ml/min/1,73 m2] 88 (±11) 87 (±10) 91 (±12) 0.17
Troponin T (mg/dl) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.01 (0.01–0.01) 0.28
Waist Circumferrence [cm] 104 (±13) 102 (±13) 104 (±13) 0.86
Operation duration [min] 240 (±60) 244 (±60) 239 (±59) 0.91
CPB duration [min] 113 (±36) 113 (±38) 114 (±34) 0.41
X-Clamp duration [min] 82 (±30) 81 (±29) 85 (±30) 0.90
HbA1c [%] 6.0 (5.6–6.6) 5.9 (5.6–6.4) 6.0 (5.7–7.2) 1.0
CK [mg/dl] 80 (55–116) 80 (60–118) 100 (57–122) 0.97
Myoglobin [mg/dl] 44 (31–54) 46 (32–59) 37 (29–52) 0.15
C-reactive protein [mg/dl] 0.3 (0.1–0.6) 0.3 (0.1–0.6) 0.2 (0.1–0.3) 0.33
Data are mean (±SD), number (%) or median (IQR). CABG: coronary artery bypass grafting, CPB: cardio pulmonary bypass, X-Clamp: Aortic clamping.
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pendent from age and preoperative eGFR.
7 (10%) of the patients had an positive Troponin T
(>0.05 mg/dl). Neither in uni- nor in multivariate analyses
preoperative troponin T showed a statically significant as-
sociation with the incidence of AKI (p > 0.05).
Discussion
In our study preoperative h-FABP serum concentration
was associated with the incidence of postoperative AKI
as well as with a longer stay on the ICU.
Previous studies have shown that postoperative h-
FABP elevation was a marker for intraoperative myocar-
dial damage with postoperative ECG changings and ele-
vation of established ischemia markers [5,7]. In a similar
setting, serum and plasma levels of h-FABP without an
ischemic incident were found to be associated with poor
outcome in end-stage heart failure patients with circula-
tory support [25]. The pathophysiology for the poorer
outcome was explained by the myocardial damageTable 2 Postoperative results
Variable All patients (n = 70)
h-FABP [ng/dl] 9.9 (9.5–10.1)
Creatinine Peak Within 48 h [mg/dl] 1.4 (±0.6)
C-reactive protein [mg/dl] 0.2 (0.1–0.5)
CK [mg/dl] 230 (145–375)
Myoglobin [mg/dl] 261 (182–410)
Troponin T [μg/l] 0.3 (0.1–0.5)
Data are mean (±SD), number (%) or median (IQR). CABG: coronary artery bypass grindicated by h-FABP elevation. None of the studies
investigated a possible association between preoperative
h-FABP concentrations with postoperative complications,
although h-FABP has been linked to preoperative risk fac-
tors like heart failure, metabolic syndrome, chronic kidney
disease or diabetes mellitus [1,2,9,11,26]. None of the cited
studies have approached our hypothesis.
The incidence of AKI is higher in our cohort than in
recent literature. This might be due to the rigorous defi-
nitions of AKIN with only a slight creatinine increase of
0.3 mg/dl. In particular as our study was performed dur-
ing the summer months, the preoperative fastening sta-
tus thus potentially causing hypovolemia might have
sensitised the kidney for intraoperative stress and thus
the incidence of AKI. It was reassuring though that only
few patients experienced more severe stages of AKI in-
cluding dialysis as we also did not observe any periopera-
tive mortality.
However, postoperative urinary l-FABP has been shown
in several recent studies as a promising marker for theAKI (n = 45) No AKI (n = 25) P-value
9.9 (9.7–10.4) 9.9 (9.2–10.1) 0.79
1.7 (±0.6) 1.0 (±0.2) <0.001
0.2 (0.1–0.4) 0.1 (0.1–0.2) 0.54
244 (175–438) 254 (138–422) 0.87
300 (212–424) 210 (137–446) 0.38
0.4 (0.2–0.7) 0.2 (0.1–0.5) 0.29
afting, CPB: cardio pulmonary bypass, X-Clamp: Aortic clamping.









Hospitalization [d] 12 (11–15) 13 (11–15) 12 (10–15) 0.35
ICU Stay [h] 44 (21–83) 46 (22–92) 22 (18–47) 0.030
Ventilation Time [h] 16 (12–20) 15 (11–20) 15 (12–21) 0.49
Data are mean (±SD), number (%) or median (IQR). CABG: coronary artery
bypass grafting, CPB: cardio pulmonary bypass, X-Clamp: Aortic clamping.
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serum levels of l-FABP have not been reported to be as-
sociated with AKI yet.
h-FABP as a marker for comorbidities
Patients with higher h-FABP values were older, had higher
creatinine values and thus lower eGFR in the present
study. Age and preoperative h-FABP were related to post-
operative AKI. These findings were similar to the results
in previous studies. A possible explanation is the associ-
ation of h-FABP with a wide spectrum of comorbidities
evident in patients undergoing cardiac surgery. DM and
metabolic syndrome, which have been described as risk
factors for AKI after CABG, were known to cause elevated
h-FABP levels [11,18,27-31]. We did not screen for all
symptoms of metabolic syndrome, but for waist circumfer-
ence, and HbA1c. Neither waist circumference nor HbA1c
were associated with AKI or with elevated preoperative h-
FABP. But in CABG patients HbA1c and waist circumfer-
ence were higher than in patients with valve surgery. In a
larger cohort of CABG patients an association between
metabolic syndrome, h-FABP and AKI might be detected.
Older age indicates increased risk for AKI after cardiac
surgery. Furthermore, elderly patients tend to have
higher h-FABP levels [1,2,18-20,30]. Both effects could
be observed in our results.
Length of ICU stay
The second finding in the present study was the associ-
ation between preoperative h-FABP and longer postope-
rative ICU treatment. A reasonable explanation for this
phenomenon was the incidence of AKI, which was associ-
ated with a longer ICU stay itself. AKI and renal failure are
known factors with an impact on ICU and hospitalizationTable 4 Univariate and multivariate models
Variable Univariate Model I Model II
Ln(h-FABP) 2.29 (1.08–4.88) 2.29 (1.08–4.89) 1.82 (0.78–4.24) 2.
eGFR 0.99 (0.97–1.02) 0.99 (0.97–1.02) -
Age 1.06 (1.00–1.11) - 1.04 (0.98–1.10)
Ln(TropT) 1.33 (0.74–2.39) - - 1.
Determinants of AKI; data is presented as OR (CI95%); ln(h-FABP) to achieve normal
backward elimination.time in cardiac surgical patients [14]. By being associated
with the incidence of AKI, h-FABP was also related to
the length of ICU stay. Longer ICU stay is associated
with higher costs and ICU capacity frequently is a limiting
factor for cardiac surgery departments. Predicting possible
lengths of stay for risk patients is of crucial importance for
the cost-effectiveness and for decent organisation of de-
partments. Therefore predictive markers need to be identi-
fied in further studies.
Postoperative h-FABP
Postoperative h-FABP was not associated with AKI in
the current study. h-FABP is a proven marker for myo-
cardial damage and is known to be elevated after cardiac
surgery. Postoperative h-FABP correlated with the estab-
lished myocardial damage markers (myoglobin, troponin
T and CK/CK-MB) in this study. None of the postopera-
tive markers had an association with AKI, however, we
might have missed true associations due to limited sam-
ple size and thus limited statistical power.
The presented study with a small number of patients
was designed to create hypotheses for future investigations
and has several limitations. A larger cohort is needed for
multivariate analyses, e.g. to adjust for the effect of age
and to investigate the different AKI stages in more detail
to also further explore the association with the length of
stay on the ICU. The screening for metabolic syndrome
was incomplete, as well as was the information on further
pathomechanisms for the incidence of AKI, such as red
cell count, left ventricular ejection fraction, and hemodynamic
instabilities. However, this information is lacking in literature
as well. Other subtypes of FABP (liver, brain) might also
interfere with h-FABP and should be measured in future
studies. If the rather strict definition of AKI by the KDIGO
can be transferred unmodified to cardiac surgical patients
needs to be discussed as well.
Conclusions
The findings of our study suggest an association between
preoperative serum h-FABP levels and postoperative in-
cidence of AKI and the length of ICU stay. The results
justify further research of FABP as a possible predictor
for adverse events after cardiac surgery within the set-
ting of prospective studies requiring larger sample sizes.Model III Model IV Final model (p < 0.1) OR (95% CI)
24 (1.01–4.94) 1.79 (0.73–4.39) 2.29 (1.08–4.88)
- 0.99 (0.96–1.02) -
- 1.03 (0.97–1.09) -
11 (0.60–2.05) 1.15 (0.62–2.13)
distribution ln of FABP was calculated; final model is based on
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